An interview on A/P Andrea Vincent discussing the status of inherited retinal dystrophy in New Zealand

Dr Leo Sheck wrote an article on subretinal fluid in non-neovascular age related macular degeneration. This article is available free of charge on the New Zealand Optics website.

This post will explore the role of anti-VEGF injections in the management of proliferative diabetic retinopathy. It will cover the effect of anti-VEGF on diabetic retinal neovascularization and vitreous haemorrhage. It will also address the common concerns regarding the use of anti-VEGF in proliferative disease, including the risk of tractional retinal detachment (crunch) and the danger in loss to follow up.

Part I of a multi series on early onset drusen, updated to include the latest in research on the role of complement factor H in the genetics of early onset drusen

This is a discussion of the role of anti-VEGF injections in the treatment of moderate to severe non-proliferative diabetic retinopathy without macula oedema

This is a discussion on the non ICG angiography diagnosis of PCV, and a comparison of EVEREST II and PLANET studies on the role of PDT in the treatment of this disease.

Many patients with neovascular AMD are on anti-coagulation. This piece will discuss the risk factors of haemorrhage in neovascular AMD, and explore if anti-coagulation will affect the risk of macula haemorrhage

A discussion on the causes of vision loss for patients with neovascular AMD treated with anti-VEGF, and how this can inform future treatment decisions.

A discussion on the latest data available regarding the risk of recurrence in neovascular age related macula degeneration following cessation of anti-VEGF injections

Our second post on this topic will discuss a number of conditions that can mimic early onset drusen.

Part I of a multi series on early onset drusen. This is on the different types of early onset drusen

Are these injections for life, or can they be stopped at some point?

A short presentation by Dr Sheck on the risk of vision loss with delays in anti-VEGF injections for neovascular AMD. This is of particular relevance during the COVID-19 pandemic.